Education Sessions
Developments in Biotech Downstream Processing (202)
| 27 October 13.30-17.00 | Track: Innovation |
ISPE CEUs: 0.2
(PDF Current as of 7 August 2008)
In the last 10 years, biotechnology processes based on mammalian cell culture have seen tremendous increases in upstream titer (from a few hundred milligrams per liter to 5-10 grams per liter). There have been few significant increases in downstream processing efficiency and the downstream processing is now becoming a significant manufacturing bottleneck. This session will explore this issue and focus on recent developments and needs in this area.
How You Will Benefit
At the end of this session, participants will be able to:
- Understand why downstream problems are developing
- Explain recent trends in DSP technology
- Articulate the newest improvements in DSP
Technical Documents - www.ISPE.org/publications
Biopharmaceutical Manufacturing Facilities Baseline®
Guide
Who Should Attend
Research, process development, and process engineering
ISPE Communities of Practice (COPs)
Biotechnology (Biotech) and Process/Product Development (PPD)
Session Speakers
- Scott Fulton, , BioSystem Development, LLC, USA
- Fran Meacle, Principal Research Scientist, Centocor R&D, USA
- Richard Schoenfeld, Principal, BioWorks Consulting, USA
- Michiel Ultee, Vice President, Process Sciences, Laureate Pharma, Inc., USA
- Peter Watler, Principal Consultant, Hyde Engineering + Consulting Inc, USA